Compass Therapeutics, Inc. — Form 8-K
Filed July 1, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 48/100
What the filing says
Compass Therapeutics disclosed its July 2026 corporate presentation containing Phase 2/3 COMPANION-002 trial results for tovecimig (CTX-009), a DLL4 x VEGF-A bispecific antibody in second-line biliary tract cancer. Primary endpoint (ORR): 18.0% vs 5.3% (p=0.0228); median PFS: 4.7 vs 2.6 months (HR=0.44, p<0.0001). The company reported $195M in cash at Q1 2026 with runway into 2028, plans Q3 2026 FDA meeting, and Q4 2026 BLA submission with potential 2H 2027 approval. Pipeline includes three additional bispecific programs (CTX-8371, CTX-10726, CTX-471) in Phase 1/early Phase 2.
Why this rating
Positive clinical data supports regulatory path for lead asset in $3B+ BTC market. However, OS confounded by 54% crossover; modest ORR (18%) vs control (5.3%) in difficult-to-treat population. Company scale ~$277M market cap; near-term milestone-driven but unproven commercial execution risk.
Extracted items
- 7.01 Reg FD disclosure
- 9.01 exhibits
View original filing on SEC.gov ↗
See more from July 1, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.